JP2023544592A5 - - Google Patents

Info

Publication number
JP2023544592A5
JP2023544592A5 JP2023520143A JP2023520143A JP2023544592A5 JP 2023544592 A5 JP2023544592 A5 JP 2023544592A5 JP 2023520143 A JP2023520143 A JP 2023520143A JP 2023520143 A JP2023520143 A JP 2023520143A JP 2023544592 A5 JP2023544592 A5 JP 2023544592A5
Authority
JP
Japan
Prior art keywords
sequence
amino acid
acid sequence
seq
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023520143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544592A (ja
JP7850143B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/053060 external-priority patent/WO2022072760A1/en
Publication of JP2023544592A publication Critical patent/JP2023544592A/ja
Publication of JP2023544592A5 publication Critical patent/JP2023544592A5/ja
Application granted granted Critical
Publication of JP7850143B2 publication Critical patent/JP7850143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023520143A 2020-10-02 2021-10-01 G13d変異を有するrasに対するhlaクラスii拘束性dq t細胞受容体 Active JP7850143B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086674P 2020-10-02 2020-10-02
US63/086,674 2020-10-02
PCT/US2021/053060 WO2022072760A1 (en) 2020-10-02 2021-10-01 Hla class ii-restricted dq t cell receptors against ras with g13d mutation

Publications (3)

Publication Number Publication Date
JP2023544592A JP2023544592A (ja) 2023-10-24
JP2023544592A5 true JP2023544592A5 (cg-RX-API-DMAC7.html) 2024-10-09
JP7850143B2 JP7850143B2 (ja) 2026-04-22

Family

ID=78676633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520143A Active JP7850143B2 (ja) 2020-10-02 2021-10-01 G13d変異を有するrasに対するhlaクラスii拘束性dq t細胞受容体

Country Status (10)

Country Link
US (1) US12655195B2 (cg-RX-API-DMAC7.html)
EP (1) EP4222169A1 (cg-RX-API-DMAC7.html)
JP (1) JP7850143B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230084524A (cg-RX-API-DMAC7.html)
CN (1) CN116710111A (cg-RX-API-DMAC7.html)
AU (1) AU2021351710A1 (cg-RX-API-DMAC7.html)
CA (1) CA3194229A1 (cg-RX-API-DMAC7.html)
GB (1) GB2615010A (cg-RX-API-DMAC7.html)
TW (2) TW202540156A (cg-RX-API-DMAC7.html)
WO (1) WO2022072760A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513651A (ja) 2021-02-26 2024-03-27 ニューヨーク ユニバーシティ 共有結合性ペプチドコンジュゲートに結合する抗体を含む組成物及び方法
WO2025056685A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V
WO2026024602A2 (en) * 2024-07-22 2026-01-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors against ras with g12d, g12v, g13d or q61r mutation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US20100286143A1 (en) * 2009-04-24 2010-11-11 Dora Dias-Santagata Methods and materials for genetic analysis of tumors
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20140134158A1 (en) * 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
SG10201913978RA (en) 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors
JP2018518177A (ja) 2015-06-16 2018-07-12 タルゴバックス エーエスエー Rasタンパク質の突然変異フラグメント
SG10201913868XA (en) 2015-09-15 2020-03-30 The United States Of America As Represented By The Secretary T cell receptors recognizing hla-cw8 restricted mutated kras
US20170319638A1 (en) 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer
GB201608052D0 (en) * 2016-05-09 2016-06-22 Univ Oslo Hf T-cell receptors which recognise frameshift mutants of TGF-beta RII
SG11201900654QA (en) 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
CN108395479B (zh) 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
AU2018335274B2 (en) 2017-09-20 2025-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II–restricted T cell receptors against mutated RAS
WO2019069125A1 (en) * 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
MX2020005765A (es) * 2017-12-04 2020-09-25 Us Health Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
SG11202012653XA (en) * 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
AU2019321608B2 (en) 2018-08-16 2024-07-25 Biontech Us Inc. T cell receptor constructs and uses thereof
US20220313803A1 (en) * 2019-01-07 2022-10-06 Brightpath Biotherapeutics Co., Ltd. Novel neoantigens and cancer immunotherapy using same
WO2020150364A1 (en) * 2019-01-15 2020-07-23 Altor Bioscience, Llc Human immunodeficiency virus-specific t cell receptors
CA3127673A1 (en) 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
WO2020191365A1 (en) * 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
MX2021015946A (es) * 2019-06-18 2022-04-18 Regeneron Pharma Receptores de linfocitos t de mage-a4 y métodos de uso de estos.
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
CA3168015A1 (en) 2020-02-12 2021-08-19 Noam LEVIN Hla class i-restricted t cell receptors against ras with g12d mutation
AU2021227406A1 (en) 2020-02-24 2022-09-29 Oblique Therapeutics Ab Kras epitopes and antibodies
WO2021250511A1 (ko) * 2020-06-10 2021-12-16 주식회사 유틸렉스 Mr1에 결합하는 t-세포 수용체 및 이의 용도

Similar Documents

Publication Publication Date Title
Trowsdale Genomic structure and function in the MHC
Sivori et al. CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies
von Boehmer The selection of the α, β heterodimeric T-cell receptor for antigen
GB2615010A (en) HLA class II-restricted DQ T cell receptors against RAS with G13D mutation
Stroynowski et al. Antigen presentation by non-classical class I molecules
Marrack et al. The T-cell repertoire for antigen and MHC
Kirberg et al. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor.
Tonegawa The molecules of the immune system
Reth Antigen receptors on B lymphocytes
Marrack et al. Comparison of peptides bound to spleen and thymus class II.
Moretta et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells.
GB2610311A (en) HLA class I-restricted T cell receptors against RAS with G12V mutation
Colonna Natural killer cell receptors specific for MHC class I molecules
Malarkannan et al. A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T cells.
van Els et al. A single naturally processed measles virus peptide fully dominates the HLA‐A* 0201‐associated peptide display and is mutated at its anchor position in persistent viral strains
Aveskogh et al. Evidence for an early appearance of modern post‐switch isotypes in mammalian evolution; cloning of IgE, IgG and IgA from the marsupial Monodelphis domestica
Franksson et al. Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene.
GB2610069A (en) HLA class II-restricted T cell receptors against RAS with G12V mutation
GB2609760A (en) HLA Class I-restricted T cell receptors against RAS with G12D mutation
JP2023527613A5 (cg-RX-API-DMAC7.html)
Guimezanes et al. Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: distinct characteristics correlated with CD8 dependence
JP2023534241A5 (cg-RX-API-DMAC7.html)
JP2022523024A5 (cg-RX-API-DMAC7.html)
Kärre Natural killer cells and the MHC class I pathway of peptide presentation
Kaufman et al. B G: we know what it is, but what does it do?